Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement

Executive Summary

Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin

Related Content

CME Accrediting Policies Being Revised As Congress Eyes Compliance Issues
Big Pharma Compliance Policies Can Add Trouble For Biotech Partners – Panel
Schering Integrity Agreement Enhances Off-Label Promotion Monitoring
Medical Education Shows Impact On Prescribing Behavior, Survey Says
Sharing The Risk: Companies Turn To Multi-Sponsored Educational Programs
Serono Integrity Agreement Requires Monitoring Off-Label Use Discussions
Corporate Integrity Agreements Offer Lessons For Voluntary Compliance Plans
Off-Label Promotion Cases Need Better Oversight In Justice Dept., WLF Says
Medicare Formularies Should Ensure Off-Label Rx Coverage – Neurologist
Neurontin, Paxil Suits Demonstrate Complications Of State Prosecutions



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts